Activities of Damiano ZOFFOLI related to 2016/2057(INI)
Plenary speeches (1)
Options for improving access to medicines (debate) IT
Amendments (8)
Amendment 157 #
Motion for a resolution
Paragraph 1
Paragraph 1
1. Recalls that the EU pharmaceutical industry is one of the most competitive industries in Europe and that; stresses that preserving a high quality of innovation is key to improving its competitivenesscontinue addressing patients' needs and to improve the competitiveness of the pharmaceutical industry;
Amendment 205 #
Motion for a resolution
Paragraph 4
Paragraph 4
4. StressNotes that the interests of the pharmaceutical industry favour short trials and fast access to the market; stress however the importance to prefer robust clinical trials in order to better assess the efficacy and safety of medicines;
Amendment 312 #
Motion for a resolution
Paragraph 13
Paragraph 13
13. Believes that a fair price for a medicine delivering additional benefits to patients should cover the cost of the drug development and production, plus a margin of profit;
Amendment 365 #
Motion for a resolution
Paragraph 17
Paragraph 17
17. Calls for EU-wide measures to guarantee the right of patients to universal, affordable, effective, safe and timely access to essential and innovative therapies, and to guarantee the sustainability of EU public health care systems; stresses that patient access to medical products is a shared responsibility of all actors of the healthcare system, including national authorities, physicians, patient organizations and manufacturers, and that optimal solutions for patient access can better emerge through collaboration between these stakeholders. Stress the important to enhance voluntary cooperation between member states aimed at greater transparency, to safeguard common interests as well as ensuring the sustainability of national health system.
Amendment 409 #
Motion for a resolution
Paragraph 20
Paragraph 20
20. Calls on the Commission to analyse through a deep, objective and unbiased study the overall impact of IP in promoting innovation and on patient access, especially the impact of supplementary protection certificates (SPCs), data exclusivity or market exclusivity on competitiveness and quality of innovation, and to set strict limits on these practices;
Amendment 452 #
Motion for a resolution
Paragraph 22 a (new)
Paragraph 22 a (new)
22a. Stress the importance to clearly demonstrate the added value in terms of R&I in marketing authorisation of so called orphan drugs.
Amendment 459 #
Motion for a resolution
Paragraph 23
Paragraph 23
23. Calls on the Commission to guarantee safety and efficacy in any fast- track approval process and to introduce the concept of conditionalguarantee that the existing schemes of early marketing authoriszation based on effectivenessare restricted to a limited range of medicines addressing "unmet medical need" and when there is no other available alternative;
Amendment 531 #
Motion for a resolution
Paragraph 28
Paragraph 28
28. Calls on the Council to promote a more rational use of medicines across the EU, and to promote campaigns and educational programmes aimed at making citizens aware of how to use medicines responsibly and on the collection of medicines that have not yet expired, the latter representing a precious asset to the poor, a huge waste and a serious financial loss for national health systems, without forgetting the negative consequences of disposal on the environment;